Crestor vs Zetia Side-Effect Profile Head-to-Head

How Rosuvastatin and Ezetimibe Work Differently

These two drugs attack LDL cholesterol from opposite ends of the metabolic pipeline. Rosuvastatin blocks the liver enzyme HMG-CoA reductase, cutting the body's own cholesterol synthesis and upregulating LDL receptors on hepatocytes [1]. Ezetimibe sits at the brush border of small intestinal enterocytes, blocking the NPC1L1 transporter that absorbs cholesterol from the gut [2]. That mechanistic difference explains almost every downstream difference in their side-effect profiles.

What Rosuvastatin Does Inside the Liver

Because rosuvastatin concentrates in hepatocytes, it creates both its efficacy (receptor upregulation) and its modest hepatotoxic signal. The FDA label for rosuvastatin notes that persistent ALT or AST elevations greater than three times the upper limit of normal occur in fewer than 1% of patients [3]. Routine liver function monitoring is no longer recommended by current guidelines for statin therapy unless symptoms appear, a position confirmed by the 2018 AHA/ACC cholesterol guideline [4].

What Ezetimibe Does at the Gut Wall

Ezetimibe's work is peripheral. It never reaches the systemic circulation in pharmacologically active concentrations sufficient to stress hepatic or skeletal muscle tissue the same way statins do. This explains why the IMPROVE-IT trial (N=18,144) reported no statistically significant difference in ALT elevations between the ezetimibe-plus-simvastatin arm and the simvastatin-alone arm [5].

Muscle-Related Side Effects: The Most Clinically Significant Difference

Muscle side effects drive more statin discontinuations than any other adverse event. Ezetimibe does not share this liability in the same way.

Rosuvastatin and Myopathy

Statin-associated muscle symptoms (SAMS) range from mild myalgia to rare rhabdomyolysis. In the JUPITER trial (N=17,802), the rosuvastatin 20 mg arm reported myalgia in roughly 7.6% of patients, compared to 6.6% in the placebo arm, a difference that was not statistically significant at the trial-wide level but is consistent with real-world prescribing data showing myalgia as the leading reason for statin discontinuation [6]. Rhabdomyolysis with rosuvastatin is rare, estimated at fewer than 1 case per 10,000 patient-years in post-marketing surveillance [3].

Dose matters considerably. Rosuvastatin 40 mg carries a meaningfully higher myopathy signal than 5 or 10 mg, and the FDA added a specific warning in 2011 noting that rosuvastatin 80 mg should not be used [3]. At 10 mg daily, the muscle risk in most patients is low enough that the American College of Cardiology considers it an acceptable first-line agent for high-intensity statin therapy [4].

Ezetimibe and Muscle Symptoms

Ezetimibe monotherapy does not carry a pharmacologically plausible mechanism for myopathy. The NPC1L1 transporter is not expressed in skeletal muscle tissue [2]. In IMPROVE-IT, creatine kinase elevations greater than 10 times the upper limit of normal occurred in 0.2% of the ezetimibe-plus-simvastatin group versus 0.2% in the simvastatin-alone group, showing no additive muscle toxicity [5].

Where confusion arises is in combination therapy. Patients who add ezetimibe to a statin because they already have statin-related myalgia sometimes attribute continued muscle symptoms to ezetimibe. A 2012 systematic review published in the European Heart Journal concluded that ezetimibe does not independently cause myopathy and that symptoms in combination patients are almost always attributable to the statin component [7].

Practical Decision Framework: Muscle Symptoms on a Statin

If a patient on rosuvastatin develops myalgia, the clinical sequence supported by the 2022 AHA Scientific Statement on statin safety is:

1. Check CK and basic metabolic panel.
2. Temporarily hold the statin for 2 to 4 weeks to establish causality.
3. If symptoms resolve, consider rechallenge at a lower dose or switch to an alternate-day regimen before abandoning statin therapy.
4. If statin therapy cannot be tolerated even at low doses, ezetimibe 10 mg daily is a reasonable substitute, though the LDL reduction will be smaller and the outcome evidence base is less strong than for high-intensity statins.

Cardiovascular Outcomes: What the Trials Actually Show

Side effects only matter in context. A drug with a tolerable side-effect profile but no mortality benefit is less useful than one with a small side-effect risk and proven outcome data.

JUPITER: Rosuvastatin in Primary Prevention

The JUPITER trial randomized 17,802 adults with LDL below 130 mg/dL but elevated high-sensitivity CRP (hsCRP > 2 mg/L) to rosuvastatin 20 mg daily or placebo [6]. The trial was stopped early at a median of 1.9 years. Rosuvastatin produced a 44% reduction in the primary composite endpoint of major cardiovascular events (nonfatal MI, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or CV death), with an absolute event rate of 0.77 per 100 person-years versus 1.36 in the placebo group [6]. All-cause mortality was also reduced by 20% (P=0.02).

The trial confirmed rosuvastatin's efficacy in a population that traditional LDL targets alone would have left untreated, an important clinical point for primary prevention decision-making.

IMPROVE-IT: Ezetimibe Added to Simvastatin After ACS

IMPROVE-IT enrolled 18,144 patients stabilized after an acute coronary syndrome, all already on simvastatin 40 mg. Patients were randomized to add ezetimibe 10 mg or placebo [5]. Over a median follow-up of 6 years, the ezetimibe group achieved a mean LDL of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone group.

The 6.4% relative reduction in the primary composite endpoint (CV death, nonfatal MI, documented unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) was statistically significant (hazard ratio 0.936, 95% CI 0.887-0.988, P=0.016) [5]. The absolute risk reduction was modest at 2.0 percentage points over 7 years, but IMPROVE-IT established for the first time that non-statin LDL lowering translates into clinical outcome benefit, validating the "lower is better" LDL hypothesis.

What the Outcome Data Means for Side-Effect Trade-Offs

Rosuvastatin has stronger, faster, and broader outcome evidence from trials including JUPITER, ASTEROID, and the broader statin meta-analyses compiled by the Cholesterol Treatment Trialists Collaboration [8]. Ezetimibe's IMPROVE-IT benefit, while real, accrued slowly over 6 years and required combination with a statin to show the effect.

This asymmetry matters when a patient asks whether the myalgia risk from rosuvastatin is worth it. For most high-risk patients, the answer from outcome data is yes.

Glucose and Diabetes Risk

Rosuvastatin carries a measurable diabetes signal. Ezetimibe does not.

Rosuvastatin and New-Onset Diabetes

In JUPITER, physicians reported new-onset diabetes in 3.0% of the rosuvastatin group versus 2.4% of the placebo group, a statistically significant difference with an odds ratio of 1.25 [6]. The FDA subsequently added a class-wide label update in 2012 noting that statins may raise fasting glucose and HbA1c [3].

A 2010 Lancet meta-analysis of 13 statin trials (N=91,140) calculated that statin therapy was associated with a 9% increased risk of incident diabetes, with approximately one extra case of diabetes per 255 patients treated for 4 years [9]. Higher-intensity statins including rosuvastatin 20 mg carried a greater signal than lower-intensity agents.

Ezetimibe and Glucose Metabolism

Ezetimibe has no pharmacological interaction with insulin secretion or insulin receptor signaling. In IMPROVE-IT, new-onset diabetes rates were statistically identical between the two arms [5]. For patients already at the threshold for type 2 diabetes, this is a meaningful differentiator when choosing between monotherapy options.

Liver Safety in Detail

Both drugs require some degree of hepatic metabolism, but their liver safety profiles differ in degree.

Rosuvastatin Hepatotoxicity

Rosuvastatin is a substrate of OATP1B1 and OATP1B3 hepatic transporters. Drug interactions that inhibit these transporters (cyclosporine, some protease inhibitors) can raise rosuvastatin plasma concentrations substantially and increase liver enzyme risks [3]. The FDA label caps the rosuvastatin dose at 5 mg daily for patients on cyclosporine [3].

Clinically significant hepatotoxicity from rosuvastatin, defined as symptomatic liver injury, is extremely rare. A 2018 review in Hepatology estimated the incidence of statin-induced clinical liver injury at roughly 1 to 3 cases per 100,000 patient-years [10].

Ezetimibe Hepatotoxicity

Ezetimibe undergoes glucuronidation in the small intestine and liver, with enterohepatic recycling. Its hepatic exposure is modest. Post-marketing data from the FDA MedWatch database through 2015 identified very few confirmed cases of ezetimibe-induced liver injury in the absence of a co-administered statin [3]. The prescribing label does note that ezetimibe plus a statin should be used with caution in patients with active liver disease, but this caution largely reflects the statin component.

Gastrointestinal Side Effects

Ezetimibe produces slightly more GI complaints than rosuvastatin in head-to-head comparator arms drawn from combination studies, though both drugs are generally well tolerated in this domain.

Ezetimibe GI Profile

The ezetimibe prescribing information lists diarrhea (occurring in 4.1% versus 3.7% placebo in pooled trials), abdominal pain (3.0% versus 2.8%), and flatulence as the most common GI adverse events [2]. These rates are small in absolute terms but consistently slightly above placebo in pooled registration data.

Rosuvastatin GI Profile

Rosuvastatin's GI adverse events are limited to nausea and constipation, each occurring in fewer than 2% of patients in registration trials [3]. Diarrhea is not a prominently listed adverse event for rosuvastatin, distinguishing it modestly from ezetimibe in patients with irritable bowel syndrome or other GI sensitivities.

Drug Interactions Compared

Rosuvastatin Interactions

Rosuvastatin's interaction profile is driven by its hepatic transporter dependence (OATP1B1/1B3) and partial CYP2C9 metabolism. Key interactions include:

• Cyclosporine: AUC increase of 7-fold; maximum rosuvastatin dose is 5 mg/day [3]
• Lopinavir/ritonavir: AUC increase of approximately 2-fold [3]
• Antacids (aluminum and magnesium hydroxide combination): reduce rosuvastatin Cmax by 54% if taken simultaneously; separate by at least 2 hours [3]
• Fenofibrate: small increase in rosuvastatin AUC, not clinically significant at standard doses [3]

Ezetimibe Interactions

Ezetimibe's interaction profile is narrower:

• Cyclosporine: increases ezetimibe AUC approximately 3.4-fold; use combination with caution [2]
• Fibrates: cholesterol gallstone risk increases when ezetimibe is combined with fenofibrate or gemfibrozil; combination not recommended with gemfibrozil [2]
• Bile acid sequestrants (cholestyramine): reduce ezetimibe Cmax by approximately 55%; administer ezetimibe at least 2 hours before or 4 hours after a sequestrant [2]

Neither drug has clinically significant interactions with warfarin at standard doses, though rosuvastatin at high doses may modestly potentiate anticoagulation and INR monitoring is recommended [3].

Special Populations: Who Gets Which Drug

Renal Impairment

Rosuvastatin requires dose adjustment in severe renal impairment (eGFR <30 mL/min/1.73 m²), where the recommended starting dose is 5 mg and the maximum is 10 mg daily [3]. Ezetimibe requires no dose adjustment for renal impairment [2].

Asian Patients

Rosuvastatin plasma concentrations are approximately 2-fold higher in patients of Asian ancestry (Japanese, Chinese, Korean, Vietnamese, Filipino, and South Asian descent) due to differences in OATP1B1 transporter activity. The FDA label recommends initiating at 5 mg in these patients [3]. Ezetimibe shows no pharmacokinetic differences based on race or ethnicity [2].

Elderly Patients

Both drugs can be used in patients aged 65 and older without automatic dose adjustment, though elderly patients face higher baseline rhabdomyolysis risk from statins due to reduced renal clearance and polypharmacy. The 2018 ACC/AHA cholesterol guidelines recommend assessing 10-year ASCVD risk and potential statin benefit before initiating therapy in adults over 75 [4].

Pregnancy

Both rosuvastatin and ezetimibe are contraindicated in pregnancy. Statins carry an FDA Category X (legacy labeling) designation based on animal teratogenicity data and theoretical inhibition of fetal cholesterol synthesis [3]. Ezetimibe is not recommended in pregnancy due to inadequate human safety data [2].

LDL Reduction: Putting the Numbers in Context

Rosuvastatin 10 mg reduces LDL by approximately 46%, and 20 mg achieves roughly 52% reduction based on pooled Phase III registration data [3]. Ezetimibe 10 mg as monotherapy reduces LDL by 18 to 20% [2].

The combination of rosuvastatin 10 mg plus ezetimibe 10 mg reduces LDL by approximately 60 to 65%, comparable to rosuvastatin 40 mg monotherapy but with a potentially lower muscle and glucose side-effect burden. A 2014 randomized trial published in the American Journal of Cardiology (N=440) found that combination rosuvastatin 5 mg plus ezetimibe 10 mg achieved similar LDL reductions to rosuvastatin 20 mg with fewer adverse events [11].

The 2022 ESC/EAS guidelines recommend combining a maximally tolerated statin with ezetimibe as a second step before adding a PCSK9 inhibitor when LDL targets (<55 mg/dL for very high-risk patients) are not met on statin monotherapy [12].

Direct Quotes From Guideline Documents

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients for whom statin therapy is indicated but cannot be tolerated at required doses, it is reasonable to use ezetimibe as an alternative to lower LDL-C and reduce risk of ASCVD events." [4]

The IMPROVE-IT investigators concluded in their primary publication: "These findings provide evidence that further lowering of LDL cholesterol with ezetimibe on a background of statin therapy reduces the risk of cardiovascular events in patients with a recent acute coronary syndrome." [5]

Side-Effect Summary Table

| Side Effect | Rosuvastatin (Crestor) | Ezetimibe (Zetia) | |---|---|---| | Myalgia | ~7.6% (JUPITER, not sig. Vs placebo) | No excess vs placebo (IMPROVE-IT) | | Rhabdomyolysis | <1 per 10,000 patient-years | Extremely rare, no mechanism | | ALT elevation >3x ULN | <1% | <1%, similar to placebo | | New-onset diabetes | OR 1.25 (JUPITER) | No signal (IMPROVE-IT) | | Diarrhea | <2% | 4.1% (pooled trials) | | Abdominal pain | <2% | 3.0% (pooled trials) | | Dose adjustment in renal impairment | Yes (eGFR <30) | No | | Asian ancestry dose reduction | Yes (start 5 mg) | No |